Phase 3 trial shows cancer vaccine intismeran autogene cuts recurrence risk by 42% versus Keytruda

At the European Society for Medical Oncology Congress, a Phase 3 trial of the personalized cancer vaccine intismeran autogene reported a 42% reduction in risk of recurrence or death compared with pembrolizumab alone.

The trial marks the first time a neoantigen-based mRNA vaccine has met its primary endpoint in oncology, highlighting the therapeutic potential of personalized vaccine approaches.

The authors note that the scientific question of efficacy is now largely settled, shifting focus to how to speed development, scale manufacturing, and ensure equitable patient access.

They warn that logistical hurdles, regulatory pathways, and reimbursement models must be addressed to bring these vaccines to patients faster than earlier genetic tests like BRCA screening.